NASDAQ · Drug Manufacturers - Specialty & Generic
COLL (COLL) Stock
$35.58
+0.54%
NASDAQ: COLL
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
COLL: Lowering target price to $33.00
Argus Research · Jul 15, 2026
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Zacks · Jul 9, 2026
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
Zacks · Jul 8, 2026
1 Small-Cap Stock Worth Your Attention and 2 That Underwhelm
StockStory · Jul 7, 2026
1 Mooning Stock to Own for Decades and 2 That Underwhelm
StockStory · Jul 3, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held1.16%
Institutions Held128.08%
Institutions Float Held129.58%
Peer Comparison
About COLL
COLL is led by CEO Vikram Karnani, employs 357 people, headquartered in US, publicly traded since 2015.
COLL stock trades at $35.58 with a market capitalization of $1.15B. The stock is valued at a price-to-earnings (P/E) ratio of 17.33, price-to-book of 3.75, price-to-sales of 1.45. Over the past 52 weeks the stock has ranged between $28.34 and $50.79, and currently trades 29.9% below its 52-week high.
On profitability, COLL generates a return on equity (ROE) of 27.41% — well above the market average, a sign of a high-quality business, return on capital employed of 61.92%, an operating margin of 15.96%, a net profit margin of 9.41%.